Central Causes of Vertigo

Central vertigo arises from pathology affecting the brainstem vestibular nuclei, their connections, or the cerebellum — structures that integrate and process vestibular, visual, and proprioceptive information for spatial orientation and balance. Distinguishing central from peripheral vertigo is one of the most consequential clinical decisions in neurology: posterior circulation stroke can present as "isolated vertigo" in up to 25% of cases, mimicking benign peripheral vestibulopathies. A missed cerebellar infarction carries mortality rates of 20–40% if edema progresses to brainstem compression. Conversely, accurately identifying peripheral vertigo spares patients from unnecessary hospitalization and costly imaging. This topic reviews the major central causes of vertigo, their clinical features, diagnostic approach, and the critical examination findings that separate dangerous central pathology from benign peripheral conditions.

Central vs. Peripheral Vertigo: Overview

The fundamental clinical distinction relies on the pattern of nystagmus, the presence of accompanying neurologic signs, and bedside vestibular testing. The following table summarizes the key differentiating features.

Posterior Circulation Stroke

Cerebellar Infarction

Cerebellar infarction is the most critical central cause of acute vertigo, as early recognition can be life-saving. The cerebellum is supplied by three paired arteries with distinct clinical syndromes.

Lateral Medullary Syndrome (Wallenberg Syndrome)

Results from lateral medullary infarction, most commonly from PICA occlusion or vertebral artery disease. It is one of the most recognizable brainstem stroke syndromes.

Pontine Stroke

• Lacunar infarctions: Small pontine infarcts may cause isolated vertigo, acute hearing loss, or gaze palsies
• Larger pontine lesions: Typically produce additional findings — internuclear ophthalmoplegia (MLF), facial weakness (CN7 nucleus), abducens palsy (CN6), conjugate gaze palsy (PPRF/MLF), "one-and-a-half syndrome"
• Anterior inferior pontine syndrome: AICA territory; vertigo + hearing loss + facial weakness + contralateral hemiparesis

AICA Infarction: The Great Mimicker

Cerebellar Hemorrhage

• Epidemiology: Accounts for ~10% of all intracerebral hemorrhages; most commonly due to hypertension (deep cerebellar nuclei) or anticoagulation; other causes include vascular malformations, metastases, and coagulopathy
• Presentation: Sudden onset vertigo, severe headache (often occipital), vomiting, truncal ataxia, inability to walk; often hypertensive at presentation
• Progression: Rapid deterioration from cerebellar edema causing brainstem compression and obstructive hydrocephalus; clinical trajectory may evolve from alert to comatose within hours
• Examination: Ipsilateral limb ataxia, gaze palsy toward lesion, reduced consciousness as compression develops; signs of brainstem compression include bilateral extensor posturing, loss of brainstem reflexes, and respiratory failure
• Clinical grading factors: Hemorrhage size (>3 cm diameter is high risk), GCS at presentation, presence of hydrocephalus, intraventricular extension, and brainstem compression all influence prognosis and surgical decision-making
• Imaging: Non-contrast CT head is the initial diagnostic study (hemorrhage appears hyperdense); CTA may reveal underlying vascular malformation; MRI once stabilized for better posterior fossa characterization
• Management:
  • Neurosurgical emergency if hemorrhage >3 cm diameter, hydrocephalus, or clinical deterioration
  • Suboccipital decompressive craniectomy with hematoma evacuation is the primary surgical intervention
  • External ventricular drain (EVD) for hydrocephalus; however, EVD alone without posterior fossa decompression risks upward transtentorial herniation
  • Reverse anticoagulation immediately (vitamin K, PCC for warfarin; idarucizumab for dabigatran; andexanet alfa for factor Xa inhibitors)
  • Blood pressure management per ICH guidelines (target SBP <140 mmHg)
• Prognosis: Without surgery, large cerebellar hemorrhages are frequently fatal; with timely decompression, outcomes can be surprisingly good given the cerebellum's capacity for compensation; small hemorrhages (<3 cm) without compression may be managed conservatively with close monitoring

Multiple Sclerosis

• Frequency: Vertigo/dizziness occurs in 20–50% of MS patients during the disease course; it is the presenting symptom in ~5%
• Mechanism: Demyelinating plaques in the vestibular nuclei, vestibular nerve root entry zone, cerebellar peduncles, or MLF
• Nystagmus patterns in MS:
  • Internuclear ophthalmoplegia (INO) — adduction lag with abducting nystagmus; bilateral INO is highly suggestive of MS in young patients
  • Downbeat nystagmus — from cervicomedullary junction plaques
  • Gaze-evoked nystagmus — cerebellar pathway involvement
  • Periodic alternating nystagmus — cerebellar nodulus/uvula
• Acute MS vertigo: May mimic vestibular neuritis; MRI brain with gadolinium shows active demyelinating lesion
• Treatment: IV methylprednisolone for acute relapses; disease-modifying therapy to prevent further attacks; symptomatic management with vestibular rehabilitation

Chiari Malformation

• Chiari type 1: Cerebellar tonsillar herniation ≥5 mm below the foramen magnum; most relevant to vestibular symptoms
• Vestibular manifestations:
  • Downbeat nystagmus: The hallmark finding; present in primary gaze, may increase in lateral gaze and on looking down; due to compression of vestibular nuclei and flocculus at the craniocervical junction
  • Oscillopsia: Subjective sensation of visual world oscillating, resulting from downbeat nystagmus
  • Positional vertigo: May closely mimic BPPV, but nystagmus is purely downbeat (rather than upbeat-torsional of posterior canal BPPV) and does not fatigue
  • Chronic disequilibrium: Unsteadiness, particularly with head extension or Valsalva maneuvers
• Associated findings: Suboccipital headache (worsened by cough/Valsalva), syringomyelia (cape-like sensory loss), lower cranial neuropathies
• Diagnosis: MRI of the craniocervical junction (sagittal view); measure tonsillar descent
• Treatment: Suboccipital decompression for symptomatic Chiari with progressive symptoms; 4-aminopyridine may reduce downbeat nystagmus (off-label)

Vestibular Paroxysmia

Episodic Ataxia Type 2

• Genetics: Autosomal dominant; mutations in CACNA1A gene (P/Q-type calcium channel) — the same gene implicated in familial hemiplegic migraine and SCA6
• Clinical features:
  • Episodic attacks of vertigo and ataxia lasting hours to days (typically 1–6 hours)
  • Precipitated by stress, exertion, caffeine, alcohol, or emotional stimuli
  • Interictal findings: gaze-evoked or downbeat nystagmus (present in >90%), mild truncal ataxia
  • Progressive cerebellar atrophy may develop over decades
• Onset: Childhood or early adulthood; family history often present but may be absent (de novo mutations)
• Diagnosis: Clinical features + interictal nystagmus + family history; genetic testing confirms CACNA1A mutation
• Treatment: Acetazolamide (250–1000 mg/day) is effective in ~60–70% of patients — mechanism involves altering cerebellar neuronal pH and excitability; 4-aminopyridine is an alternative (RCT evidence); migraine preventives may also help
• Differential: Episodic ataxia type 1 (KCNA1; briefer attacks in seconds-minutes, with myokymia; responds to carbamazepine)

Tumors

Vestibular Schwannoma (Acoustic Neuroma)

• Epidemiology: Incidence ~1 per 100,000/year; accounts for 80–90% of CPA tumors; bilateral vestibular schwannomas are pathognomonic of NF2 (now termed NF2-related schwannomatosis)
• Presentation: Progressive unilateral sensorineural hearing loss (the dominant symptom in >90%) >> tinnitus (high-pitched, continuous) >> disequilibrium; true episodic vertigo is uncommon because the slow growth allows central compensation
• Examination: Asymmetric hearing loss on Weber/Rinne; may have absent corneal reflex (CN5 compression) or facial weakness (CN7) with larger tumors; Hitselberger sign (loss of sensation on the posterior wall of the external auditory canal) is an early finding
• Vestibular testing: Caloric testing often shows unilateral weakness; vHIT may be normal (slow deafferentation allows compensation); hyperventilation-induced nystagmus (beats away from tumor side) is a useful bedside clue; VEMPs may be absent or reduced on the tumor side
• Diagnosis: MRI with gadolinium of the internal auditory canal; audiometry shows asymmetric SNHL (>15 dB difference at ≥2 frequencies); ABR may show prolonged I–III or I–V interpeak latencies
• Management:
  • Observation with serial MRI (every 6–12 months initially): appropriate for small tumors (<2 cm), elderly patients, or when hearing is good and tumor is not growing
  • Stereotactic radiosurgery (Gamma Knife, CyberKnife): for tumors ≤3 cm; high tumor control rate (90–95%); hearing preservation rate 50–70% at 5 years
  • Microsurgery: via retrosigmoid, translabyrinthine, or middle fossa approach depending on size and hearing status; best for large tumors (>3 cm) with brainstem compression
  • Choice depends on size, hearing status, patient age, growth rate, and patient preference

Other CPA Tumors

• Meningioma: Second most common CPA tumor (5–10%); may present similarly to schwannoma; enhances homogeneously on MRI with dural tail; broader-based attachment to the petrous bone; hearing preservation is better with surgery than for schwannoma
• Epidermoid cyst: Restricted diffusion on DWI (key distinguishing feature from arachnoid cyst); may cause trigeminal neuralgia, hemifacial spasm, and vestibular symptoms; typically follows CSF signal on T1/T2 but is bright on DWI/FLAIR
• Metastases: Consider in patients with known malignancy (breast, lung, melanoma) and new-onset vestibular symptoms or cranial neuropathies; may seed the CPA or internal auditory canal
• Hemangioblastoma: Consider in patients with von Hippel-Lindau disease; occurs in the cerebellum; highly vascular, enhances intensely

Imaging in Central Vertigo

Clinical Decision-Making: Approach to Acute Vertigo

Management Principles

Acute Central Vertigo

• Posterior circulation stroke: Standard acute stroke management (IV thrombolysis within 4.5 h, thrombectomy for large vessel occlusion per current guidelines); antiplatelet/anticoagulation per etiology; neurosurgical consultation for large cerebellar infarction with edema
• Cerebellar hemorrhage: Blood pressure management, reversal of anticoagulation, neurosurgical evaluation for decompression
• MS relapse: IV methylprednisolone 1 g/day × 3–5 days

Chronic and Episodic Central Vertigo

• Vestibular paroxysmia: Carbamazepine or oxcarbazepine
• Episodic ataxia type 2: Acetazolamide or 4-aminopyridine
• Downbeat nystagmus (any cause): 4-aminopyridine (3,4-DAP) has RCT evidence for symptomatic improvement; clonazepam or baclofen as alternatives
• Vestibular migraine: Migraine preventive therapy (see dedicated topic)
• Vestibular rehabilitation: Effective for chronic vestibular symptoms from central or peripheral causes; habituation, gaze stabilization, and balance training

Cerebellar Degenerative Disorders and Vertigo

Progressive cerebellar degeneration, whether from genetic ataxias, paraneoplastic causes, or alcohol-related toxicity, often presents with chronic dizziness and disequilibrium rather than acute episodic vertigo.

Key Conditions

Vertebral Artery Dissection

• Epidemiology: Important cause of posterior circulation stroke in young adults (<50 years); may follow minor neck trauma, chiropractic manipulation, sports, or occur spontaneously
• Presentation: Ipsilateral neck pain and occipital headache followed by vertigo, ataxia, and brainstem signs (lateral medullary syndrome, cerebellar infarction); headache may precede stroke by hours to weeks
• Vestibular manifestations: Isolated vertigo may be the presenting symptom before stroke develops; any young patient with acute vertigo and ipsilateral neck/head pain should be evaluated for dissection
• Diagnosis: CTA or MRA of the neck (fat-saturated T1 axial images show intramural hematoma as crescent of hyperintensity); conventional angiography is rarely needed
• Treatment: Antiplatelet or anticoagulation (no randomized data showing superiority of either); treatment typically continued for 3–6 months; stenting for recurrent symptoms despite medical therapy
• Prognosis: Recanalization occurs in the majority within 3–6 months; recurrence risk is ~1%/year; connective tissue disorders (Ehlers-Danlos type IV, Marfan, fibromuscular dysplasia) increase recurrence risk

Drug-Induced Central Vertigo

Medications are a frequently overlooked cause of central vestibular symptoms, particularly in the elderly or patients on multiple medications.

Bilateral Vestibulopathy

While not a "central" cause of vertigo per se, bilateral vestibulopathy is a chronic vestibular disorder that presents with disequilibrium and oscillopsia rather than vertigo, and its recognition and workup often involve central vestibular assessment.

• Clinical features: Oscillopsia (visual blurring with head movement, such as reading signs while walking), chronic imbalance (worse in the dark or on uneven surfaces), NO episodic vertigo (symmetric bilateral loss does not create asymmetric signal that produces spinning sensation)
• Causes: Ototoxic medications (gentamicin is the most common cause), bilateral Ménière disease, autoimmune inner ear disease, bilateral vestibular schwannomas (NF2), superficial siderosis, meningitis, idiopathic (up to 50%)
• Diagnosis: Bilateral positive head impulse test or bilateral reduced caloric responses (total SPV <20°/sec); vHIT showing bilaterally reduced VOR gain (<0.6); bilateral absence of VEMPs; dynamic visual acuity loss ≥3 lines
• Bárány Society criteria (2017): Chronic vestibular syndrome with unsteadiness and oscillopsia, bilaterally reduced VOR (vHIT gain <0.6 bilaterally, or bilateral caloric weakness), not better explained by another diagnosis
• Treatment: Vestibular rehabilitation (cornerstone — improves gaze stabilization and balance through substitution strategies); avoid further ototoxic exposure; cochlear implant with vestibular component is under investigation

References

1. Kattah JC, Talkad AV, Wang DZ, Hsieh YH, Newman-Toker DE. HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging. Stroke. 2009;40(11):3504–3510.
2. Newman-Toker DE, Hsieh YH, Camargo CA, Pelletier AJ, Butchy GT, Edlow JA. Spectrum of dizziness visits to US emergency departments: cross-sectional analysis from a nationally representative sample. Mayo Clin Proc. 2008;83(7):765–775.
3. Lee H, Sohn SI, Cho YW, et al. Cerebellar infarction presenting isolated vertigo: frequency and vascular topographical patterns. Neurology. 2006;67(7):1178–1183.
4. Edlow JA, Gurley KL, Newman-Toker DE. A new diagnostic approach to the adult patient with acute dizziness. J Emerg Med. 2018;54(4):469–483.
5. Kim JS, Lee H. Inner ear dysfunction due to vertebrobasilar ischemic stroke. Semin Neurol. 2009;29(5):534–540.
6. Strupp M, Lopez-Escamez JA, Kim JS, et al. Vestibular paroxysmia: diagnostic criteria. J Vestib Res. 2016;26(5-6):409–415.
7. Jen JC, Graves TD, Hess EJ, Bhatt M, Bhatt S, Bhatt M. Primary episodic ataxias: diagnosis, pathogenesis, and treatment. Brain. 2007;130(10):2484–2493.
8. Choi KD, Lee H, Kim JS. Vertigo in brainstem and cerebellar strokes. Curr Opin Neurol. 2013;26(1):90–95.
9. Tarnutzer AA, Berkowitz AL, Robinson KA, Hsieh YH, Newman-Toker DE. Does my dizzy patient have a stroke? A systematic review of bedside diagnosis in acute vestibular syndrome. CMAJ. 2011;183(9):E571–E592.
10. Strupp M, Kalla R, Claassen J, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxia. Neurology. 2011;77(3):269–275.
11. Lee H, Kim JS, Chung EJ, et al. Infarction in the territory of anterior inferior cerebellar artery: spectrum of audiovestibular loss. Stroke. 2009;40(12):3745–3751.
12. Saber Tehrani AS, Kattah JC, Mantokoudis G, et al. Small strokes causing severe vertigo: frequency of false-negative MRIs and nonlacunar mechanisms. Neurology. 2014;83(2):169–173.
13. Brandt T, Dieterich M. Vestibular syndromes in the roll plane: topographic diagnosis from brainstem to cortex. Ann Neurol. 1994;36(3):337–347.
14. Kim JS, Cho KH, Lee H. Isolated labyrinthine infarction as a harbinger of anterior inferior cerebellar artery territory infarction with normal diffusion-weighted brain MRI. J Neurol Sci. 2009;278(1-2):82–84.